Skip to main content
. 2018 Nov 3;32(6):1587–1590. doi: 10.21873/invivo.11418

Table I. Summary of the characteristics of the nine patients who received ceritinib (CER) after alectinib (ALC).

graphic file with name in_vivo-32-1588-i0001.jpg

M, Male; F, female; PS, Eastern Cooperative Oncology Group Performance Status; Ad, adenocarcinoma; LCNEC, large-cell neuroendocrine carcionoma; CRZ, crizotinib; Cis, cisplatin; PEM, pemetrexed; Cb, carboplatin; PAC, paclitaxel, BEV, bevacizumab; NIVO, nivolumab; ERL, erlotinib; DOC, docetaxel; CPT, irinotecan; GEM, gemcitabine; S-1, tegafur/gimeracil/oteracil; PR, partial response; SD, stable disease; PD, progressive disease; ILD, interstitial lung disease. *Censored.